Ocuphire Pharma, Inc. (OCUP) Misses Q4 EPS by 16c

Ocuphire Pharma, Inc. (NASDAQ: OCUP) reported Q4 EPS of ($0.21), $0.16 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $1.69 million versus the consensus estimate of $5.36 million.

For earnings history and earnings-related data on Ocuphire Pharma, Inc. (OCUP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c